Kidney Trouble Short-Lived in Most Liver Transplan... ( Study finds short-term dysfunction wh...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

Kidney Trouble Short-Lived in Most Liver Transplant Patients

Date:5/6/2008

Study finds short-term dysfunction while awaiting operation rarely turns chronic

TUESDAY, May 6 (HealthDay News) -- Few patients who have short-term kidney dysfunction while awaiting a liver transplant develop severe kidney problems once they have their transplant, says a U.S. study.

An increasing number of patients have kidney dysfunction while awaiting liver transplantation, which has led to debate among transplant experts about which patients are likely to develop kidney dysfunction after liver transplant and should be considered for combined liver/kidney transplantation.

This kind of decision is extremely difficult due to the lack of a reliable predictive model and the increasing shortage of organs available for transplant, according to background information in the study, led by Ranjeeta Bahirwani, of the University of Pennsylvania.

The study included 60 people who had liver transplants between March 2000 and August 2005, and had serum creatinine of at least 1.5 mg/dl for at least two weeks prior to, and at the time of, transplantation.

The patients were followed for a median of 36 months after their transplant, and only eight of them had significant kidney dysfunction. Those who had kidney dysfunction for more than 12 weeks before transplant were at increased risk for severe post-transplant kidney problems.

Diabetes and serum creatinine level at the time of transplant were other major predictors of severe post-transplant kidney problems.

"Our data are reassuring that the vast majority of patients with pre-transplant renal insufficiency do not develop advanced stage 4 or 5 chronic kidney disease," after liver transplant, the study authors wrote.

Serious post-transplant kidney disease was particularly rare among patients whose pre-transplant serum creatinine was elevated for less than 12 weeks. The researchers suggested that elevated serum creatinine levels for more than
'/>"/>

1

GOOD

Page: 1 2
Related medicine news :

1. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
2. Expenses Overshadow Optimism for Kidney Failure Patients
3. Katie Lee Joel to Conduct Cooking Demonstration for Local Patients With Chronic Kidney Disease
4. Lowering Blood Protein Wont Help Kidney Patients
5. DaVita Teammates Bicycling 230 Miles for Kidney Disease Education
6. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
7. Metabolic syndrome heightens risk for development of uric-acid kidney stones
8. Nighttime Home Dialysis a Boon for Kidney Patients
9. New Survey Reveals Kidney Patients Concern About Medicare Policies
10. Nations Largest Dialysis Patient Organization Recognizes the Achievements of Patients and Leaders in Kidney Care
11. Kidney Awareness Time (KAT) Walk Raised Awareness and $400,000 for Kidney Education and Prevention Programs

Post Your Comments:

[0] NICE guidelines ration affordable osteoporosis drugs [0] Menopause Often Means Worsening Cholesterol [0] China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 [1] New Board Gains Control of U.S. Shanghai Chemical Corporation [0] Surgery on beating heart thanks to robotic helping hand

Other Medicine News:Health News:Cogdell Spencer Announces Commencement of Common Stock Offering 2 Health News:Cogdell Spencer Announces Commencement of Common Stock Offering 3 Health News:Hanger Orthopedic Group, Inc. Announces Two Acquisitions Totaling $5.3 Million of Annual Net Revenue 2 Health News:LCA Hails US Court of Appeals Decision to Affirm Lower Court Ruling Tobacco Companies Guilty of Massive Fraud and Deception 2 Health News:LCA Hails US Court of Appeals Decision to Affirm Lower Court Ruling Tobacco Companies Guilty of Massive Fraud and Deception 3 Health News:National study finds youth baseball-related injuries down 25 percent 2 Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 2 Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 3 Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 4 Health News:Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer 2 Health News:Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer 3 Health News:Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer 4

Cogdell Spencer Announces Commencement of Common Stock Offering Hanger Orthopedic Group, Inc. Announces Two Acquisitions Totaling $5.3 Million of Annual Net Revenue LCA Hails US Court of Appeals Decision to Affirm Lower Court Ruling Tobacco Companies Guilty of Massive Fraud and Deception National study finds youth baseball-related injuries down 25 percent More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer

Breaking Medicine Technology:Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2 Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3 Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4 Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2 Imagenetix Inc to Present at the 2009 RedChip New York Equities Conference 14251 1 Imagenetix Inc to Present at the 2009 RedChip New York Equities Conference 14251 2 Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 1 Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 2 Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 3 Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 4 Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 1 Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 2 Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 3 Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 4

[0] Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders [0] Mylan Receives Approval for Generic Version of Antiepileptic Keppra(R) 1000 mg [0] Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer

Other Medicine Technology:Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 2 Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 3 Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 4 Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent 2 Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent 3

Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent

Medicine Products:

Continuous Flow Cystoscopes Prolieve™ Thermodilatation System The Prostatron® System The Targis® System

Kidney Trouble Short-Lived in Most Liver Transplan...( Study finds short-term dysfunction wh...),Health